<DOC>
	<DOCNO>NCT01539642</DOCNO>
	<brief_summary>The purpose study compare efficacy safety Sufentanil NanoTab PCA System/15 mcg Placebo Sufentanil NanoTab PCA System management acute moderate severe post-operative pain open abdominal surgery .</brief_summary>
	<brief_title>A Multicenter , Randomized , Double-Blind , Placebo-Controlled Trial Evaluate Efficacy Safety Sufentanil NanoTab PCA System/15 mcg ( Zalviso™ ) Treatment Post-Operative Pain Patients After Open Abdominal Surgery</brief_title>
	<detailed_description />
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Sufentanil</mesh_term>
	<criteria>Male female patient 18 year old Patients schedule undergo open abdominal surgery ( include laparoscopicassisted ) general anesthesia spinal anesthesia include intrathecal opioids operation . Postsurgical patient admit PACU expect remain hospitalized acute postoperative pain require parenteral opioids least 48 hour surgery . Patients take opioid 30 consecutive day , daily dose 15 mg morphine ( equivalent ) , within past 3 month prior surgery ( e.g . 3 dos per day Vicodin® , Norco® , Lortab® 5 mg hydrocodone per tablet ) . Patients allergy hypersensitivity opioids . Female patient pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>In patient , post operative pain</keyword>
	<keyword>Adult post-operative inpatient expect require parenteral opioid analgesia least 48 hour open abdominal surgery</keyword>
</DOC>